Scholarlink

Background <p>Renal interstitial fibrosis (RIF) is a hallmark pathological process in the progression of chronic kidney disease (CKD). However, effective therapies to halt or reverse RIF remain limited. Emerging evidence implicates ferroptosis as a critical contributor to RIF. Rosiglitazone (Rosi), a widely used thiazolidinedione, exhibits anti-ferroptotic activity but suffers from poor aqueous solubility, limited renal specificity, and systemic side effects.</p> Results <p>Here, we constructed a renal tubular epithelial cell-targeted nano-based drug delivery system—Rosi-loaded, K3 peptide–modified, PEGylated hollow polydopamine(HPDA) nanoparticles (Rosi@HPDA-PEG-K3 NPs). This system displayed excellent biocompatibility and lesion-specific targeting, achieving prolonged retention in fibrotic kidneys. The in vitro and in vivo experiment demonstrated that this nano-based drug delivery system inhibited ferroptosis through downregulation of ACSL4, iron ion chelation, and ROS scavenging. Concurrently, it stabilized mitochondrial membrane potential and synergistically suppressed inflammatory responses, ultimately attenuating RIF.</p> Conclusions <p>In summary, Rosi@HPDA-PEG-K3 NPs deliver Rosi specifically to renal renal tubular epithelial cells(TECs)and exert an anti-RIF effect through the integration of ferroptosis inhibition, mitochondrial protection, and inflammation modulation. Our study establishes a nanotherapeutic platform with precise targeting and multifunctional efficacy, highlighting its scientific rigor and the clinical translational potential of RIF.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

HPDA-based tubule-targeting nanoplatform alleviates oxidative stress and ferroptosis for the reversal of renal interstitial fibrosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月13日

查看全文
  • Zheng Xiao,
  • Peng Luo,
  • Guoli Li,
  • Huifang Tan,
  • Chen Zhou,
  • Dong Zeng,
  • Yinyin Chen,
  • Ying Li

摘要

Background

Renal interstitial fibrosis (RIF) is a hallmark pathological process in the progression of chronic kidney disease (CKD). However, effective therapies to halt or reverse RIF remain limited. Emerging evidence implicates ferroptosis as a critical contributor to RIF. Rosiglitazone (Rosi), a widely used thiazolidinedione, exhibits anti-ferroptotic activity but suffers from poor aqueous solubility, limited renal specificity, and systemic side effects.

Results

Here, we constructed a renal tubular epithelial cell-targeted nano-based drug delivery system—Rosi-loaded, K3 peptide–modified, PEGylated hollow polydopamine(HPDA) nanoparticles (Rosi@HPDA-PEG-K3 NPs). This system displayed excellent biocompatibility and lesion-specific targeting, achieving prolonged retention in fibrotic kidneys. The in vitro and in vivo experiment demonstrated that this nano-based drug delivery system inhibited ferroptosis through downregulation of ACSL4, iron ion chelation, and ROS scavenging. Concurrently, it stabilized mitochondrial membrane potential and synergistically suppressed inflammatory responses, ultimately attenuating RIF.

Conclusions

In summary, Rosi@HPDA-PEG-K3 NPs deliver Rosi specifically to renal renal tubular epithelial cells(TECs)and exert an anti-RIF effect through the integration of ferroptosis inhibition, mitochondrial protection, and inflammation modulation. Our study establishes a nanotherapeutic platform with precise targeting and multifunctional efficacy, highlighting its scientific rigor and the clinical translational potential of RIF.

Graphical Abstract